🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Alan Bonder at #TLM24: addressing the Itch. #PBC ✅If there is itch> get a detailed view of the itching ✅Sx-based therapy is important to improve QoL and should be a priority when caring PBC patients. ✅Cholestatic sx aren’t longitudinal, can be up/down, so ask all the time!

Thanks to all who attended our presentations at #TLM2024 throughout the weekend. We had a great time catching up with many faces old and new, and learning about the exciting advancements in liver disease. If you would like to learn more about the data presented, visit our

The #RareDiseaseDay campaign launches today, kicking off 100 days of raising awareness for conditions like PSC, facing huge unmet needs. By uniting globally with researchers, policymakers, and healthcare professionals, we can improve care and advance research 💙 #LetsBeatPSC

We had a great time connecting with the #liver community at AASLD' The Liver Meeting 2024 in San Diego, CA. Thank you for joining us! #TLM24

#Autoimmune disease can run in families but it may not be the same disease

Our President and CEO, Dannielle Appelhans, recently spoke to @MattPillar of BioProcess Online. Learn more about our approach to treating #AutoimmuneDiseases with therapies developed using our #nanoparticle platform for antigen-specific immune tolerance: bit.ly/4ir9GQK

Did you know?! You can prescribe patient-friendly educational resources about cirrhosis (text and video) directly to your patient's inbox! You can also print these resources to keep on hand anytime: cirrhosiscare.ca/patient-referr…… #LiverTwitter

🩺Direct your patients and caregivers to CirrhosisCare.ca for a comprehensive set of modules on cirrhosis. It’s a valuable resource for learning about symptoms, treatments, and managing their health. cirrhosiscare.ca/patients/ #LiverTwitter

🌟 What’s it about? Biliary abnormalities in autoimmune hepatitis (AIH) and interface hepatitis in primary biliary cholangitis (PBC) can often be misinterpreted, leading to therapeutic mistakes that negatively impact patients.

Your Rare Experience Matters! NORD launched the new #LivingRareStudy to collect insights from YOUR real-life experience of living with a #RareDisease. Are you or a loved one living with a rare disease? Learn more and share your story! LivingRareStudy.org

🌟 New Release: The EASL Clinical Practice Guidelines for the Management of Patients with Decompensated Cirrhosis is now available on the EASL Guidelines App. Download today and access expert guidance at your fingertips! 📲easl.eu/news/launching… @EASLNews @Jhepatology

In the largest biomarker validation study performed in cirrhosis, the GALAD score is better than alpha-fetoprotein (AFP) at detecting early stage HCC. 🔗ow.ly/i8ZA50UFpPt 🖋️ Elliot Tapper Marina Serper, MD, MS Juan Pablo (JP) Arab, MD 

As temperatures dip, the most obvious signs of dehydration often disappear. Dr. Saundra Nguyen helps understand the importance of staying hydrated in cold weather and how to identify when it’s time to drink more water. bit.ly/3BTclij #hydration #ColdWeather

In 2024, our dedicated team at Mayo Clinic completed over 2,000 solid #organtransplants. Patients came to us from 47 states, and they are at the heart of everything we do. Thank you to our amazing team and the remarkable patients who inspire us every day. #DonateLife

With the approval of new 2nd line therapies, clinicians / patients will be discussing adding another treatment and which one. Great video discussion on this. While aimed at clinicians, patients will benefit also pharmacytimes.com/view/treatment…

As #RareDiseaseDay approaches, consider joining NORD on Feb. 25 at the The Boston Globe’s inaugural Rare Disease Summit. NORD CEO Pamela Gavin is among the featured speakers who will discuss driving change for the #RareDisease community. It's free to attend virtually, and we’re

NORD is providing emergency aid for #RareDisease patients affected by the #LAfires—including short-term lodging, car rental, limited home repairs, and more. Please spread the word to those you know in #LosAngeles! To request assistance, contact [email protected]

Rare Disease Day is February 28th.

Linerixibat, presented today at #EASLCongress, shows strong potential to become the first global therapy for pruritus in #PBC! 🧪 Phase 3 GLISTEN trial showed rapid, meaningful itch relief & better sleep. ✅ Well-tolerated, with expected AEs (diarrhoea, abdominal pain) A

Results at the liver meeting 2025